The U.S. Supreme Court rejected a bid by Johnson & Johnson to overturn a $70 million jury verdict against the pharmaceutical company for J&J’s failure to warn about risks associated with off-label uses of the antipsychotic drug Risperdal.
The American Medical Association (AMA) doubled down on the organization’s stance against using off-label medicines such as hydroxychloroquine and chloroquine to treat COVID-19 patients.
